Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Cash And Cash Equivalents At Carrying Value of $89.74 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed a decrease of -14.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), BIOCRYST PHARMACEUTICALS INC's Cash And Cash Equivalents At Carrying Value has grown by 301.6%.
- Historical annual values: Fiscal year 2025: $89.74 million | Fiscal year 2024: $104.71 million | Fiscal year 2023: $110.64 million | Fiscal year 2022: $304.77 million | Fiscal year 2021: $504.39 million | Fiscal year 2020: $272.13 million | Fiscal year 2019: $114.17 million | Fiscal year 2018: $26.73 million | Fiscal year 2017: $50.28 million | Fiscal year 2016: $22.10 million | Fiscal year 2015: $28.90 million | Fiscal year 2014: $54.54 million | Fiscal year 2013: $21.16 million | Fiscal year 2012: $20.89 million | Fiscal year 2011: $16.44 million | Fiscal year 2010: $13.62 million | Fiscal year 2009: $41.13 million | Fiscal year 2008: $22.34 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: